Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental VL-program districts with non-program districts.


Journal

Tropical medicine & international health : TM & IH
ISSN: 1365-3156
Titre abrégé: Trop Med Int Health
Pays: England
ID NLM: 9610576

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 20 12 2018
medline: 30 7 2019
entrez: 20 12 2018
Statut: ppublish

Résumé

At the time when Nepal is on the verge of reaching the maintenance phase of the Visceral Leishmaniasis (VL) elimination program, the country is facing new challenges. The disease has expanded to 61 of the country's 75 districts including previously non-endemic areas where there is no control or patient management program in place. This study aimed to assess which elements of the surveillance and reporting systems need strengthening to identify cases at an early stage, prevent further transmission and ensure sustained VL elimination. In a cross-sectional mixed-method study, we collected data from two study populations in VL program and non-program districts. From February to May 2016, structured interviews were conducted with 40 VL patients, and 14 in-depth and semi-structured interviews were conducted with health managers. The median total delay from onset of symptoms to successful reporting to the Ministry of Health was 68.5 days in the VL-program and 83 days in non-program districts. The difference in patient's delay from the onset of symptoms to seeking health care was 3 days in VL-program and 20 days in non-program districts. The diagnostic delay (38.5 days and 36 days, respectively), treatment delay (1 vs. 1 days) and reporting delay (45 vs. 36 days) were similar in program and non-program districts. The diagnostic delay increased three-fold from 2012, while treatment and reporting delay remained unchanged. The main barriers to surveillance were: (i) lack of access and awareness in non-program districts; (ii) growing private sector not included in and not participating to referral, treatment and reporting; (iii) lack of cooperation and coordination among stakeholders for training and deployment of interventions; (iv) insufficient validation, outreach and process optimisation of the reporting system. Corrective measures are needed to maintain the achievements of the VL elimination campaign and prevent resurgence of the disease in Nepal. A clear patient referral structure, reinforcement of report notification and validation and direct relay of data by local hospitals and the private sector to the district health offices are needed to ensure prompt treatment and timely and reliable information to facilitate a responsive system of interventions.

Identifiants

pubmed: 30565348
doi: 10.1111/tmi.13189
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Pagination

192-204

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

DaJull Lim (D)

General Medicine Department, University of Freiburg, Freiburg, Germany.

Megha Raj Banjara (MR)

Central Department of Microbiology, Tribhuvan University, Kathmandu, Nepal.

Vivek Kumar Singh (VK)

Public Health and Infectious Disease Research Centre (PHIDReC), Kathmandu, Nepal.

Anand Ballabh Joshi (AB)

Public Health and Infectious Disease Research Centre (PHIDReC), Kathmandu, Nepal.

Chitra Kumar Gurung (CK)

Public Health and Infectious Disease Research Centre (PHIDReC), Kathmandu, Nepal.

Murari Lal Das (ML)

BP Koirala Institute of Health Sciences, Dharan, Nepal.

Greg Matlashewski (G)

McGill University, Montreal, Canada.

Piero Olliaro (P)

UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland.

Axel Kroeger (A)

UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland.
Center for Medicine and Society, University of Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH